Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy
- 1 July 2005
- journal article
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 118 (13) , 2923-2933
- https://doi.org/10.1242/jcs.02404
Abstract
Introduction Partner notification (PN) is a process aiming to identify, test and treat the sex partners of people (index patients) with sexually transmitted infections (STIs). Accelerated partner therapy (APT) is a PN method whereby healthcare professionals assess sex partners, by telephone consultation, before giving the index patient antibiotics and STI self-sampling kits to deliver to their sex partner(s). The Limiting Undetected Sexually Transmitted infections to RedUce Morbidity programme aims to determine the effectiveness of APT in heterosexual women and men with chlamydia and determine whether APT could affect Chlamydia trachomatis transmission at population level. Methods and analysis This protocol describes a cross-over cluster randomised controlled trial of APT, offered as an additional PN method, compared with standard PN. The trial is accompanied by an economic evaluation, transmission dynamic modelling and a qualitative process evaluation involving patients, partners and healthcare professionals. Clusters are 17 sexual health clinics in areas of England and Scotland with contrasting patient demographics. We will recruit 5440 heterosexual women and men with chlamydia, aged ≥16 years. The primary outcome is the proportion of index patients testing positive for C. trachomatis 12-16 weeks after the PN consultation. Secondary outcomes include: proportion of sex partners treated; cost effectiveness; model-predicted chlamydia prevalence; experiences of APT. The primary outcome analysis will be by intention-to-treat, fitting random effects logistic regression models that account for clustering of index patients within clinics and trial periods. The transmission dynamic model will be used to predict change in chlamydia prevalence following APT. The economic evaluation will use mathematical modelling outputs, taking a health service perspective. Qualitative data will be analysed using interpretative phenomenological analysis and framework analysis. Ethics and dissemination This protocol received ethical approval from London—Chelsea Research Ethics Committee (18/LO/0773). Findings will be published with open access licences. Trial registration number ISRCTN15996256.Keywords
This publication has 39 references indexed in Scilit:
- MBNL1 Is the Primary Determinant of Focus Formation and Aberrant Insulin Receptor Splicing in DM1Journal of Biological Chemistry, 2005
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Pre-mRNA splicing and human diseaseGenes & Development, 2003
- Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cellsHuman Molecular Genetics, 2002
- Loss of the Muscle-Specific Chloride Channel in Type 1 Myotonic Dystrophy Due to Misregulated Alternative SplicingMolecular Cell, 2002
- Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cellsHuman Molecular Genetics, 2002
- The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiationHuman Molecular Genetics, 2001
- In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcriptsNucleic Acids Research, 2001
- Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcriptsProceedings of the National Academy of Sciences, 1997
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberPublished by Elsevier ,1992